Stoke Therapeutics Prepares for Phase 3 Study of Zorevunersen for Dravet Syndrome
Stoke Therapeutics, Inc. (NASDAQ: STOK) recently announced plans to launch a Phase 3 study of zorevunersen, aiming to develop the first disease-modifying treatment for Dravet syndrome. The company disclosed this information in a Form 8-K filing with the Securities and Exchange Commission. The Phase 3 study, named EMPEROR, will assess zorevunersen’s efficacy in reducing major […]
More Stories
Trump Announces EPA Will Roll Back Biden-Era Methane Regulations on Oil and Gas Producers
By Tom Gantert President Donald Trump announced Tuesday night in Lubbock, Texas, that his administration would roll back Biden-era methane...
Treasury Department Ends Ownership Reporting for US Small Businesses
By Owen Evans The Treasury Department on Aug. 11 finalized a rule permanently exempting U.S. companies and individuals from reporting...
US Consumer Confidence Rebounds Sharply in October: Conference Board
By Andrew Moran U.S. consumer confidence rebounded sharply in October, logging its first increase in four months, according to The...
Microsoft Offers Voluntary Buyouts to 60,000 Employees
By Andrew Moran Microsoft is offering voluntary buyouts to about 60,000 employees, around one-quarter of its total workforce, the software...
SBS Executives Questioned on Why Outlet Refers to Hamas as ‘Militants’ Not ‘Terrorists’
By Crystal-Rose Jones Executives at Australia’s multicultural Special Broadcasting Service (SBS) were asked to explain why the outlet does not...
What a New Roof Really Costs in Texas: A 2026 Budget Guide
The roof is the most expensive part of a house that most owners never look at. One spring storm can...